Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierluigi Viale

Showing results (191-200 of 466) with videos related to

Pageof 47
Sort By:
Infectious Diseases (London, England)|June 21, 2019
Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver diseaseLeonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
The New Microbiologica|October 11, 2017
Characterization of an IncL/M plasmid carrying blaOXA-48 in a Klebsiella pneumoniae strain from ItalyPaolo Gaibani, Erika Scaltriti, Chiara Benni, et al.
European Journal of Clinical Pharmacology|September 30, 2010
Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patientsLeonardo Calza, Laura Mosca, Daria Pocaterra, et al.
International Journal of Antimicrobial Agents|December 23, 2008
Treatment of pyogenic (non-tuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicinPierluigi Viale, Mario Furlanut, Luigia Scudeller, et al.
BMC Public Health|April 12, 2014
Trend of microbiologically-confirmed tuberculosis in a low-incidence setting with high immigration ratesGiulia Lombardi, Paola Dal Monte, Agnese Denicolò, et al.
HIV Clinical Trials|February 13, 2014
Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patientsLeonardo Calza, Elisa Vanino, Caterina Salvadori, et al.
Le Infezioni in Medicina|March 31, 2015
A prospective evaluation of maraviroc administration in patients with advanced HIV disease and multiple comorbidities: focus on efficacy and tolerability issuesRoberto Manfredi, Leonardo Calza, Ginevra Marinacci, et al.
Le Infezioni in Medicina|February 11, 2022
Complicated carbapenem-resistant infections: a treatment pathway analysis in Italian sitesEmanuele Durante-Mangoni, Lorenzo Bertolino, Claudio Mastroianni, et al.
The New Microbiologica|July 16, 2019
Factors associated with vitamin D deficiency in HIV-1 infected patients on combination antiretroviral therapy: a case-control studyLeonardo Calza, Giulia di Pietro, Vincenzo Colangeli, et al.
Scandinavian Journal of Infectious Diseases|September 21, 2012
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavirLeonardo Calza, Filippo Trapani, Caterina Salvadori, et al.
Pageof 47

Showing results (191-200 of 466) with videos related to

Sort By:
Pageof 47
Infectious Diseases (London, England)|June 21, 2019
Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver diseaseLeonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
The New Microbiologica|October 11, 2017
Characterization of an IncL/M plasmid carrying blaOXA-48 in a Klebsiella pneumoniae strain from ItalyPaolo Gaibani, Erika Scaltriti, Chiara Benni, et al.
European Journal of Clinical Pharmacology|September 30, 2010
Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patientsLeonardo Calza, Laura Mosca, Daria Pocaterra, et al.
International Journal of Antimicrobial Agents|December 23, 2008
Treatment of pyogenic (non-tuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicinPierluigi Viale, Mario Furlanut, Luigia Scudeller, et al.
BMC Public Health|April 12, 2014
Trend of microbiologically-confirmed tuberculosis in a low-incidence setting with high immigration ratesGiulia Lombardi, Paola Dal Monte, Agnese Denicolò, et al.
HIV Clinical Trials|February 13, 2014
Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patientsLeonardo Calza, Elisa Vanino, Caterina Salvadori, et al.
Le Infezioni in Medicina|March 31, 2015
A prospective evaluation of maraviroc administration in patients with advanced HIV disease and multiple comorbidities: focus on efficacy and tolerability issuesRoberto Manfredi, Leonardo Calza, Ginevra Marinacci, et al.
Le Infezioni in Medicina|February 11, 2022
Complicated carbapenem-resistant infections: a treatment pathway analysis in Italian sitesEmanuele Durante-Mangoni, Lorenzo Bertolino, Claudio Mastroianni, et al.
The New Microbiologica|July 16, 2019
Factors associated with vitamin D deficiency in HIV-1 infected patients on combination antiretroviral therapy: a case-control studyLeonardo Calza, Giulia di Pietro, Vincenzo Colangeli, et al.
Scandinavian Journal of Infectious Diseases|September 21, 2012
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavirLeonardo Calza, Filippo Trapani, Caterina Salvadori, et al.
Pageof 47